Optimización del uso de Antimicrobianos en el Hospital Víctor Lazarte Echegaray, abril 2017 – marzo 2019

• Autor: Flores Mendieta, Katherin Vanessa
• Formato: tesis de grado
• Fecha de Publicación: 2019
• Institución: Universidad Nacional de Trujillo
• Repositorio: UNITRU-Tesis
• Lenguaje: español
• OAI Identifier: oai:dspace.unitru.edu.pe:20.500.14414/12821
• Enlace del recurso: https://hdl.handle.net/20.500.14414/12821
• Nivel de acceso: acceso abierto
• Materia: Programa de Optimización de Antimicrobianos; Ceftriaxona; Cefepime; Vancomicina

The purpose of this report on pre-professional practices was to compare the consumption of medications before and after the implementation of the Antimicrobial Optimization Program (PROA) at the Víctor Lazarte Echegaray Hospital. The sample consisted of patients treated in the Medicine and Surgery B services, before the implementation of the PROA in the period April 2017 - March 2018 and after the implementation of the PROA in the period April 2018 - March 2019. The method used It was the international technique for measuring the consumption of medicines, Defined Daily Dose, with which the consumption was evaluated by means of DDD / 100camas / day of ceftriaxone 1g, cefepime 1g and vancomycin 500mg. The results before the implementation of the PROA in the Medicine and Surgery B Services were for ceftriaxone 5.63 (62%) and 19.90 (77%), cefepime 5.73 (72%) and 1.26 (74%) ) and vancomycin 6.50 (69%) and 2.99 (77%); while after the implementation of the PROA, 3.50 (38%) and 5.85 (23%), cefepime 2.20 (28%) and 0.45 (26%) and vancomycin 2.92 were obtained in ceftriaxone. 31%) and 0.89 (23%) DDD / 100camas / day respectively. Using the T-Student test, statistical significance was determined with 95% confidence to compare before and after the implementation of PROA for ceftriaxone, cefepime and vancomycin in Medicine with values of 0.0111; 0.0104 and 0.0269 and Surgery B 0.0170; 0.0174 and 0.0210 respectively. Therefore, it was concluded that there is a decrease in the consumption of ceftriaxone, cefepime and vancomycin after the implementation of the PROA in the services of Medicine and Surgery B.